AnaptysBio has transformed into a royalty management company centered on Jemperli, an oncology drug commercialized by GSK. The company now operates with minimal costs, targeting a 95% EBIT margin and holding over $140 million in net cash, eliminating previous R&D expenses. Jemperli royalties are expected to increase with sales, and after settling an obligation to Sagard by mid-2027, AnaptysBio will benefit from high-margin, growing royalty streams. Positive trial data and potential label expansions for Jemperli, along with a $100 million share buyback plan, support the company's new focus despite some risks related to litigation and revenue concentration.
Reddit joined the S&P 500 index on August 18, 2026, replacing AvalonBay Communities, which may increase demand for its shares from index-tracking funds. Morgan Stanley maintained an Overweight rating on Reddit but lowered its price target from $240 t...
BJ's Wholesale Club reported quarterly earnings per share of $1.36 and revenue of $6.23 billion, surpassing analyst expectations. The growth was driven by budget-conscious shoppers and strong membership momentum, pushing sales beyond the company's fo...
UBS analyst Radi Sultan set a $40 price target for GitLab Inc., suggesting a nearly 5% downside from its current $42.08 share price. Despite this cautious outlook, the rise of AI is boosting demand for GitLab's software development platform, especial...
DraftKings (DKNG) shares closed at $25.03 on August 20, 2026, well below their 52-week high of $48.78, reflecting significant volatility. Wall Street analysts mostly maintain a positive outlook, with many recommending Buy or Strong Buy and average pr...
Bitcoin surged about 24% over the past week to around $76,844, driven by short liquidations and recovering inflows into U.S. spot Bitcoin ETFs. Standard Chartered's analyst Geoff Kendrick suggests that the current rally could push Bitcoin closer to i...
